Inamed buys Collagen Aesthetics for $142 million
This article was originally published in Clinica
Inamed has stepped in to buy Collagen Aesthetics for $16.25 a share, valuing the company at $142 million. The move follows an unsolicited bid in March from Inamed's closest competitor in implants, Mentor, which offered $14.50 a share or $126 million for the Palo Alto, California-based company. Collagen Aesthetics, formerly Collagen, had sales of $84 million in the 1999 financial year. Inamed had annual sales of $144 million.
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.